IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.47
+0.68%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +23.0%
- Operating cash flow
- +24.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +74.6%
- EPS
- +53.6%
Three-year CAGR
- Revenue
- +175.9%
- EBITDA
- +103.1%
- EBIT
- +89.1%
- Net income
- +92.4%
- EPS
- +93.2%
- Free cash flow
- +5.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026